Basilea Pharmaceutica International Ltd, Allschwil

Basilea Pharmaceutica International Ltd, Allschwil, is a commercial-stage biopharmaceutical company headquartered in Allschwil, Switzerland. Established in 2000 as a spin-off from F. Hoffmann-La Roche, the company is dedicated to the discovery, development, and commercialization of innovative medicines to address severe bacterial and fungal infections. Its core mission is to be a leading provider of such medicines, striving to make a difference for patients through expertise, care, and persistence.

The company's portfolio features two key marketed hospital brands: Cresemba (isavuconazole), an antifungal used for invasive fungal infections, and Zevtera (ceftobiprole), an antibiotic for severe bacterial infections. Basilea operates through a business model that involves collaborating with a network of licensing and distribution partners to commercialize its products globally, rather than direct marketing. Its robust pipeline includes several anti-infective assets, such as the broad-spectrum antifungal fosmanogepix (currently in Phase 3 clinical trials) and the oral antibiotic ceftibuten-ledaborbactam etzadroxil (Phase 3-ready), alongside earlier-stage candidates like BAL2062 and BAL2420.

Under the leadership of CEO David Veitch, Basilea has demonstrated consistent profitability since 2022, driven by strong in-market sales of its commercial products. Recent notable developments include the US launch of Zevtera in May 2025 and the acquisition of rights to fosmanogepix and ceftibuten-ledaborbactam etzadroxil, which have significantly strengthened its late-stage clinical pipeline. The company has also secured additional funding from BARDA and CARB-X for its antibiotic development programs in 2026. Cresemba has achieved strong double-digit sales growth, establishing itself as the largest branded antifungal for invasive fungal infections worldwide.